Konja Glucomannan Clinical Overview
一级毛片免费完整视频Glucomannan has been investigated for its effects on weight reduction, diabetes, constipation, cholesterol, lung cancer, and atopic diseases, as well as its use as a prebiotic. There are issues of quality concerning the evidence to support use for these indications.
一级毛片免费完整视频Clinical studies of glucomannan in diabetes, cholesterol control, and obesity have used dosages of 1 to 13 g daily.
一级毛片免费完整视频Given the risk of esophageal and gastric obstruction, use is not recommended in patients with structural abnormalities of the esophagus or gut.
一级毛片免费完整视频Information regarding use during pregnancy and lactation is lacking. Until more information is obtained, use is not recommended in pregnant or breast-feeding women.
Because of glucomannan's potential ability to lower blood glucose, use caution in patients receiving oral hypoglycemic agents, insulin, or alternative medicines that could potentially lower glucose levels. Additionally, glucomannan may reduce the bioavailability of other oral medications. Thus, it is recommended that other medications be taken 1 hour before or 4 hours after glucomannan administration.
Severe esophageal and GI obstruction have been reported with glucomannan tablets. The hypoglycemic effects are potentially dangerous to patients with diabetes. Glucomannan has been linked in case reports to cholestatic hepatitis and occupational asthma. Minor adverse effects are normally GI related and include diarrhea, flatulence, abdominal discomfort, and bloating.
Glucomannan given at 500 mg/day for 18 months to rats demonstrated no toxicity. Data suggest diarrhea, abdominal pain, and flatulence occur with dosages more than 5 g daily.